Pfizer, Inc
Pfizer Inc. is a U.S.-based global biopharmaceutical company that discovers, develops, manufactures, markets, sells, and distributes prescription medicines and vaccines worldwide. Its business is organized around a biopharma portfolio, with additional contract development and manufacturing activities and selected R&D collaboration services.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueBranded prescription medicines sold across therapeutic areas including cardiovascular, migraine, oncology, and infectious disease.
Preventive vaccines for pediatric, adult, and respiratory use, including COVID-19 and pneumococcal products.
Oral antiviral treatment for COVID-19 infection.
CDMO services and specialty active pharmaceutical ingredient supply through PC1.
Strategic guidance and end-to-end research services for selected biotech partners.
Customers
Pfizer sells primarily to healthcare providers, payors, wholesalers, pharmacies, hospitals, and government or public health buyers. Demand is driven by clinical need, formulary access, vaccination programs, and purchasing contracts, with some products also sold through collaboration partners or shared commercialization arrangements.
Buy and prescribe Pfizer medicines and vaccines for patient treatment and prevention; access and clinical outcomes drive usage.
Purchase and distribute Pfizer products into retail and institutional channels; important for broad market reach.
Do not usually buy product inventory, but strongly influence access, rebates, and formulary placement.
Purchase vaccines and certain treatments through procurement programs and public health campaigns.
Use Pfizer’s R&D, development, and commercialization capabilities for selected programs.
Strategy
Pfizer’s strategy centers on improving R&D productivity, expanding commercial execution in key categories, and allocating capital toward future growth opportunities. The company also emphasizes digital enablement, including automation and AI, to support productivity, development speed, and operating efficiency.
Pfizer depends on a strong pipeline to replace mature products and sustain long-term growth.
Execution in major franchises supports uptake, access, and lifecycle management.
Automation and data-driven decision making can improve speed and efficiency across the business.
The company is positioning its portfolio and pipeline for future revenue replacement and expansion.
Geography
Q1/2026Pfizer operates globally, with commercial activity split between the U.S. and international markets. In the disclosed 2025 revenue geography analysis, the U.S. accounted for 58% of revenue and international markets for 42%, showing a broad mix of domestic and ex-U.S. demand.
Risks
Pfizer faces product concentration, pricing, regulatory, and demand risks typical of large pharmaceutical companies, plus specific exposure to COVID-19 products and patent-driven competition. Its revenue base is also sensitive to payer pressure, generic entry, reimbursement changes, and the timing of approvals, launches, and supply agreements.
- COVID-19 product demand volatilityImpact: HighLikelihood: High
Comirnaty and Paxlovid depend on infection rates, recommendations, and coverage decisions that can change quickly.
Exposure - Pricing and access pressureImpact: HighLikelihood: High
Payors, PBMs, and providers increasingly demand rebates and lower prices, reducing net realized revenue.
Exposure: U.S. commercial portfolio
- Patent expiry and generic/biosimilar competitionImpact: HighLikelihood: High
Loss of exclusivity can sharply reduce sales as lower-cost alternatives enter the market.
Exposure: Mature branded products and off-patent portfolios
- Regulatory and reimbursement uncertaintyImpact: MediumLikelihood: High
Approvals, label changes, and coverage decisions affect whether products can be marketed and reimbursed.
Exposure - Supply chain and manufacturing disruptionImpact: MediumLikelihood: High
Global production and distribution depend on complex manufacturing, sourcing, and logistics networks.
Exposure: Worldwide operations
Accounting
Judgemental itemsGross sales are reduced by rebates, chargebacks, allowances, and returns estimated at sale date.
Impact: Can materially affect reported net revenue and product growth rates
Demand is concentrated in certain seasons and can vary with infection rates and recommendations.
Impact: Quarterly revenue comparability can be uneven
Large acquired product rights and business combinations require impairment testing and valuation judgments.
Impact: Can create significant non-cash charges if product outlook weakens
Pharma companies face litigation and regulatory claims that require accrual estimates.
Impact: Can affect operating expenses and liabilities
Similar listed companies
Publicly listed companies with a comparable business focus.
Merck & Co., Inc.
MRK · Pharmaceutical Preparations
GSK plc
GSK · Pharmaceutical Preparations
GSK plc is a global biopharma company that develops and commercializes prescription medicines, vaccines, and specialty treatments.
Moderna, Inc.
MRNA · Biological Products, (No Diagnostic Substances)
Novavax, Inc
NVAX · Biological Products, (No Diagnostic Substances)
Novavax is a U.S.-based biotechnology company focused on developing and commercializing protein-based vaccines and vaccine-related technologies.
Gilead Sciences, Inc
GILD · Biological Products, (No Diagnostic Substances)
Gilead Sciences is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases.
Sanofi
SNY · Pharmaceutical Preparations
Sanofi is a biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines and vaccines.
Last updated: 24/09/2026